Investors Shareholders

About
Teams
Responsibility
Investments
Media

Current portfolio

Aelin Therapeutics

Novel therapeutic modality to induce functional knockdown of a target protein

Sector
Healthcare
Country
Belgium
Fund
LSP 5
Entry
2017
Web
aelintx.com

Sector
Healthcare
Country
Belgium
Fund
LSP 5
Entry
2017
Web
aelintx.com

Latest news

30 May 2023
Bulletin from EQT AB’s Annual Shareholders’ Meeting 2023
29 May 2023
Francesco Starace to join EQT Infrastructure as Partner – brings deep experience and expertise in energy and transition related industries
15 May 2023
EQT launches EQT Nexus: Enabling individuals’ access to the world of EQT
12 May 2023
EQT Infrastructure to acquire a majority stake in Italy’s largest mobile network from Wind Tre
08 May 2023
The World Economic Forum publishes "Private Markets Impact Investing: A Turning Point"

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of newsRegulatory NewsEQT News

Preferred languageEnglishSwedish

Email address

Offices

Europe
North America
- New York
- San Francisco
APAC

About

EQT Playbook
Fund investors
Purpose and Culture
EQT Foundation
- EQT Foundation
Careers
- Life at EQT
- EQT Academy
Motherbrain

Teams

Roles

Responsibility

Future-proofing
- Climate Action
- Diversity and Inclusion

Business Segments

Private Capital
Real Assets

Investments

Portfolio

Shareholders

About EQT AB Group
IPO on Nasdaq Stockholm
Reports and Presentations
Corporate Governance
About the Share

Media

Newsroom
- News
- Reports and presentations

Contact

Media
- Press Contact
Follow

Legal

Sustainable Finance Disclosure
Complaints Handling Procedure
Glossary and Definitions
Policies
Cookie Policy
Terms and Conditions

About

Teams

Responsibility

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180